Cantor Fitzgerald Reiterates $17.00 Price Target for Horizon Pharma (HZNP)

Horizon Pharma (NASDAQ:HZNP) received a $17.00 price target from equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 13.79% from the company’s previous close.

HZNP has been the topic of several other research reports. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Sunday, September 10th. Zacks Investment Research cut Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Jefferies Group boosted their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. Finally, Cowen restated a “buy” rating on shares of Horizon Pharma in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $18.75.

Shares of Horizon Pharma (NASDAQ HZNP) traded up $0.04 on Wednesday, hitting $14.94. The company had a trading volume of 1,104,200 shares, compared to its average volume of 3,347,260. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $18.31. The firm has a market cap of $2,440.00, a price-to-earnings ratio of -4.91, a PEG ratio of 1.26 and a beta of 1.31.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The business had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. During the same period in the previous year, the firm earned $0.70 EPS. Horizon Pharma’s quarterly revenue was up 30.1% compared to the same quarter last year. research analysts anticipate that Horizon Pharma will post 0.72 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in HZNP. Bank of Montreal Can increased its holdings in shares of Horizon Pharma by 16.3% during the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 1,378 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Horizon Pharma by 82.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 69,626 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in Horizon Pharma by 2,170.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 21,700 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in Horizon Pharma by 12.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 1,466 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in Horizon Pharma by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 210,843 shares of the biopharmaceutical company’s stock valued at $2,503,000 after buying an additional 6,871 shares in the last quarter. Institutional investors own 86.58% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Reiterates $17.00 Price Target for Horizon Pharma (HZNP)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/27/cantor-fitzgerald-reiterates-17-00-price-target-for-horizon-pharma-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

What are top analysts saying about Horizon Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Horizon Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit